Magenta Therapeutics Appoints Anne McGeorge to Board of Directors

6/24/19

Anne McGeorge, M.S., CPA,

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that it has appointed Anne McGeorge, M.S., CPA, to its board of directors. Ms. McGeorge will also serve as chair of the Magenta audit committee.

“We are delighted to welcome Anne McGeorge to the Magenta board,” said Jason Gardner, D.Phil., President and Chief Executive Officer, Magenta Therapeutics. “Ms. McGeorge has extensive financial and strategic leadership experience in healthcare. Her diverse expertise will be invaluable to Magenta as we build a fully integrated company with a singular focus on curing patients with autoimmune diseases, blood cancers and genetic diseases.”

“Magenta has a bold vision to revolutionize the field of stem cell transplant to allow many more patients to benefit from its power to reset the immune system -- a vision that is personally important to me through my work with Be The Match, the leading global stem cell transplant organization,” said Ms. McGeorge. “I look forward to working with the team at Magenta to help them bring their transformative therapies to patients across multiple disease areas.”

Ms. McGeorge is an operating partner at Havencrest Healthcare, a growth equity fund specializing in the healthcare industry; and a board member at Dioko Health Ventures, a healthcare venture fund. She previously spent more than a decade as managing partner of the U.S. and Global Healthcare practice at Grant Thornton, an independent audit, tax and advisory firm; and prior to that was a healthcare partner at audit and tax firms Deloitte, LLP and Arthur Andersen, LLP.

Ms. McGeorge is a member of the board of directors and the audit/finance and new technology committees of Be The Match, a non-profit organization dedicated to helping patients access life-saving stem cell transplants. She also sits on the steering committee of the Carolinas and Tampa Bay chapters of 2020 Women on Boards, an organization focused on increasing diversity on public company boards. Ms. McGeorge teaches a financial leadership course at the University of North Carolina, Chapel Hill, Gillings School of Public Health.

Ms. McGeorge earned a B.B.A. in accounting from the College of William and Mary, and an M.S. in Accounting from the University of Virginia.

About Magenta Therapeutics Headquartered in Cambridge, Mass., Magenta Therapeutics is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune diseases, blood cancers and genetic diseases. By creating a platform focused on critical areas of unmet need, Magenta Therapeutics is pioneering an integrated approach to allow more patients to receive one-time, curative therapies by making the process more effective, safer and easier.

Recent Deals

Interested in advertising your deals? Contact Edwin Warfield.